Previous 10 | Next 10 |
2024-06-20 09:02:55 ET More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly oral weight-loss candidate orforglipron is pote...
2024-06-20 07:35:13 ET More on Evotec SE Evotec SE (EVO) Q1 2024 Earnings Call Transcript Evotec SE 2024 Q1 - Results - Earnings Call Presentation Evotec SE (EVO) Q4 2023 Earnings Call Transcript Evotec to exit gene therapy business, close Austria site ...
2024-06-18 13:49:28 ET More on Eli Lilly Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Eli Lilly’s oral...
2024-06-18 13:30:13 ET Eli Lilly’s ( NYSE: LLY ) success with a newer class of diabetes and weight-loss drugs has the potential to be repeated with other products in its research pipeline, healthcare analysts said Tuesday at the Seeking Alpha Investing Summit in New York.... ...
2024-06-18 12:54:18 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...
2024-06-18 11:26:22 ET Summary Novo Nordisk is a growth stock that continues to pleasantly surprise me and investors with the pace of its development of product candidates for the treatment of endocrine diseases. The company's share price reflects optimism about its diabetes franc...
2024-06-18 11:16:16 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Ozempic drives more demand for small...
2024-06-17 14:50:10 ET More on FlexShares Trust - FlexShares Quality Dividend Defensive Index Fund: QDEF: FlexShares' Defensive Dividend ETF Fails To Stand Out QDEF: Great Name, But Holdings Don't Validate Seeking Alpha’s Quant Rating on FlexShares Trust - Fle...
2024-06-17 14:28:29 ET More on Utilities Select Sector SPDR ETF, Health Care Select Sector SPDR, etc. XLU: Utilities Are Attractive, Some More Than Others Not Impressed By Either Of The Stories That Have Been Powering XLU XLU: Join Billionaires Trading Short-Term Pai...
2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...